Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053312 | 0.92 | HTR1A (0.76) | HTR1ASLC6A2SLC6A3 | |
| SCHEMBL10052737 | 0.90 | HTR1A (0.80) | HTR1A | |
| SCHEMBL349866 | 0.88 | HTR1A (0.69) | HTR1ASLC6A2SLC6A4SLC6A3KCNK2 | |
| SCHEMBL7431833 | 0.88 | HTR1A (0.74) | HTR1ASLC6A2SLC6A4SLC6A3KCNK2 | |
| SCHEMBL7443118 | 0.87 | HTR1A (0.71) | HTR1ASLC6A2SLC6A4SLC6A3KCNK2 | |
| SCHEMBL7427608 | 0.87 | HTR1A (0.71) | HTR1ASLC6A2SLC6A4SLC6A3KCNK2 | |
| SCHEMBL351933 | 0.87 | HTR1A (0.81) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10052723 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A4SLC6A3KCNK2 | |
| SCHEMBL10021769 | 0.86 | HTR1A (0.80) | HTR1ASLC6A2SLC6A3 | |
| SCHEMBL7427735 | 0.86 | HTR1A (0.67) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0576766-A1 | Propanolamine derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 1994-01-05 | — | — | EP | claimed |
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7893261-B2 | bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity | BAYLOR UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893261-B2 | bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity | BAYLOR UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | BAYLOR UNIVERSITY | 2008-06-05 | — | — | US | disclosed |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | BAYLOR UNIVERSITY | 2008-06-05 | — | — | US | disclosed |
| EP-0576766-A1 | Propanolamine derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | HTR2A, HTR2C, HTR1A | HTR1A 3/4885SLC6A2 15/4885SLC6A4 8/4885 |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | HTR2A, HTR2C, HTR1A | HTR1A 3/4885SLC6A2 15/4885SLC6A4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.